Eliminating pharmaceutical rebates: a wild goose chase?

21 October 2020
matthew_majewski_andy_parece_large-1

Reducing patient healthcare costs is imperative, write Matthew Majewski (pictured above, on left) and Andrew Parece, vice presidents of Charles River Associates, in a Special Report.

In July, the Trump administration restated its intention to remove rebates for Medicare Part D drugs as one of several new Executive Orders aimed at lowering prescription drug costs. One of the administration's goals in revisiting the rebate elimination plan is to reduce the potential for unintended incentives created by the protection of rebates under the safe-harbor provisions of the Anti-Kickback Statute.

As the 2020 election approaches, one of the key areas of focus for both parties is how to make healthcare costs more affordable for patients, particularly the cost of prescription drugs. Over time, patient costs for prescription drugs have been increasing, in part because such costs have been shifting from fixed patient co-payments that vary by formulary tier to percentage-based co-insurance payments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical